TLR7 Antibody (4G6) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-27332

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human, Mouse

Cited:

Human, Mouse

Applications

Validated:

Knockout Validated, Immunohistochemistry, Western Blot, Flow Cytometry, Flow (Intracellular), Immunocytochemistry/ Immunofluorescence, Knockdown Validated, CyTOF-ready

Cited:

Knockout Validated, Immunohistochemistry-Paraffin, Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, IF/IHC, Knockdown Validated

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # 4G6

Format

BSA Free

Concentration

1 mg/ml

View all TLR7 Antibodies »

Product Specifications

Immunogen

A partial human TLR7 recombinant protein (amino acids 562-839) was used as the immunogen.

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 24126361)

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Description

Novus Biologicals Knockout (KO) Validated Mouse TLR7 Antibody (4G6) - BSA Free (NBP2-27332) is a monoclonal antibody validated for use in IHC, WB, Flow and ICC/IF. Anti-TLR7 Antibody: Cited in 18 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.

Scientific Data Images for TLR7 Antibody (4G6) - BSA Free

Flow Cytometry: TLR7 Antibody (4G6) - BSA Free [NBP2-27332]

Flow Cytometry: TLR7 Antibody (4G6) - BSA Free [NBP2-27332]

Flow Cytometry: TLR7 Antibody (4G6) [NBP2-27332] - THP-1 cells were stained with TLR7 (4G) NBP2-27332 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature, followed by Dylight488-conjugated anti-mouse secondary antibody.
Flow (Intracellular): TLR7 Antibody (4G6) - BSA Free [NBP2-27332]

Flow (Intracellular): TLR7 Antibody (4G6) - BSA Free [NBP2-27332]

Flow (Intracellular): TLR7 Antibody (4G6) [NBP2-27332] - Analysis using the PE conjugate of NBP2-27332. Staining of TLR7 in 10^6 human BDCM cells (red) and 0.5 ug of mouse IgG1 isotype control (green). this antibody was used for this test.
Flow Cytometry: TLR7 Antibody (4G6) - BSA Free [NBP2-27332]

Flow Cytometry: TLR7 Antibody (4G6) - BSA Free [NBP2-27332]

Flow Cytometry: TLR7 Antibody (4G6) [NBP2-27332] - Analysis using Azide Free version of NBP2-27332. THP-1 cells were stained with TLR7 (4G) NBP2-25274 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin.
View 9 more images

Applications for TLR7 Antibody (4G6) - BSA Free

Application
Recommended Usage

Flow (Intracellular)

5 ug/ml

Flow Cytometry

1-2ug/10^6cells

Immunocytochemistry/ Immunofluorescence

1:500-1:5000. Use reported in scientific literature (PMID 22610069)

Immunohistochemistry

1:50 - 1:200. Use reported in scientific literature (PMID 31092820)

Knockdown Validated

reported in scientific literature (PMID 31730654)

Western Blot

10ug/ml~
Application Notes
This antibody is CyTOF ready.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: TLR7

Toll-like receptor 7 (TLR7) is a type I transmembrane protein expressed on the surface of endosomes and has a role in pathogen-associated molecular patterns (PAMPs) recognition and host defense (1-3). TLR7 is primarily expressed in the brain, placenta, spleen, stomach, and lungs (4). TLR7 recognizes microbial single stranded RNA (ssRNA), specifically guanosine and its derivatives (1-3). Human TLR7 cDNA encodes a 1049 amino acid (aa) protein with a theoretical molecular weight (MW) of 120.9 kDa (4). The TLR7 protein consists of a signal sequence, an 813 aa extracellular domain containing leucine-rich repeats (LRRs) which form a horseshoe-like shape, a 21 aa transmembrane domain, and a 189 aa cytoplasmic domain with cytosolic Toll-interleukin-1 receptor homology (TIR) domains (1,2,4). TLR7 and its fellow subfamily members, TLR8 and TLR9, possess a characteristic Z-loop between two LRRs with proteolytic Z-loop processing required for TLR activation (2). Z-loop cleavage in TLR7 allows for guanosine and uridine-rich ssRNA binding to the 1st and 2nd ligand binding site, respectively (2). The TIR domain associates with the adaptor protein myeloid differentiation primary response protein (MyD88) to initiate downstream signaling (1-3,5,6). Following activation by PAMPs, TLR7 dimerizes and bound MyD88 interacts with interleukin-1 receptor-associated kinase-4 (IRAK-4) (1,5). Together the complex recruits IRAK-1 and IRAK-2, which become phosphorylated, and interact with tumor necrosis factor receptor-associated factor 6 (TRAF6) (1,5). TRAF6 induces the activation of mitogen-activated protein kinase (MAPK), nuclear factor-kappaB (NF-kappaB), and interferon-regulatory factor 7 (IRF7), leading to interferon production and pro-inflammatory cytokine secretion associated with immune response (1,5).

While TLRs play an important role in innate immune response, dysfunction in the TLR-MyD88 signaling cascade has also been reported in various autoimmune disorders (5,6). Elevated expression of TLR7 is associated with increased risk of system lupus erythematosus (SLE), an autoimmune disease involving B cell hyperactivity (6,7). Studies involving mouse models has also found that increased TLR7 expression predisposes mice to a lupus-like disease (7). Therapeutics targeting TLR7 have been developed to either enhance or inhibit its activity depending on the circumstance. For example, TLR7 agonists such as imiquimod, resiquimod, and 852A are used to increase TLR7 activity for treatment of cancers and to fight viral infections (7,8). On the other hand, TLR7 antagonists inhibit its activation and have been developed to combat chronic immune stimulation as seen in inflammatory and autoimmune diseases (8).

References

1. Petes C, Odoardi N, Gee K. The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome. Front Immunol. 2017;8:1075. https://doi.org/10.3389/fimmu.2017.01075

2. Maeda K, Akira S. TLR7 Structure: Cut in Z-Loop. Immunity. 2016;45(4):705-707. https://doi.org/10.1016/j.immuni.2016.10.003

3. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007;220:251-269. https://doi.org/10.1111/j.1600-065X.2007.00572.x

4. Uniprot (Q9NYK1)

5. Zheng C, Chen J, Chu F, Zhu J, Jin T. Inflammatory Role of TLR-MyD88 Signaling in Multiple Sclerosis. Front Mol Neurosci. 2020;12:314. https://doi.org/10.3389/fnmol.2019.00314

6. Chi H, Li C, Zhao FS, et al. Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol. 2017;8:304. https://doi.org/10.3389/fphar.2017.00304

7. Fillatreau S, Manfroi B, Dorner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(2):98-108. https://doi.org/10.1038/s41584-020-00544-4

8. Patinote C, Karroum NB, Moarbess G, et al. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020;193:112238. https://doi.org/10.1016/j.ejmech.2020.112238

Long Name

Toll-like Receptor 7

Alternate Names

toll-like receptor 7

Gene Symbol

TLR7

Additional TLR7 Products

Product Documents for TLR7 Antibody (4G6) - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for TLR7 Antibody (4G6) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.